CONTACT

+91 80 2808 2808

info@biocon.com

Hope.
Now within
reach.

Aiming to reach a billion patients worldwide with affordable, lifesaving medicines.

Kiran Mazumdar-Shaw
Executive Chairperson, Biocon Limited For a complete and accurate understanding, please read the full press release at this link >> "The integration of Biocon Biologics Limited into Biocon Limited represents the next chapter in our evolution. Strategically, Biocon will be one of the few companies offering both biosimilars and generics at a global scale. As the only company with biosimilar insulins and generic GLP1 peptides, Biocon is uniquely positioned to comprehensively address the needs of patients living with diabetes. Together with our combined oncology and immunology portfolios, this creates a differentiated offering addressing the world’s most pressing healthcare needs."

Meeting unmet
patient needs.

Our novel biologics address unmet medical needs across the world.

Research
saves lives.
Accelerating drug innovation and development for patients globally.

Biocon Continues to be
Among ‘Top 10 Global
Employers’ Ranked No. 9, recognized as an innovative leader with loyal employees and dynamic leadership driving change
>>

gLiraglutide for Diabetes
and Obesity Launched
in the UK
>>

Biocon Biologics
Launches Yesintek^TM
Biosimilar Ustekinumab
in the United States
>>

Biocon Biologics

WHO WE ARE

Driven by purpose.

Biocon is a global biopharmaceutical company transforming access to healthcare through affordable innovation. Guided by our shared mission, we are focused on delivering lifesaving therapies to patients everywhere.

MORE >>

WHO WE ARE

Driven by purpose.

We are a global biopharmaceutical company with the belief that everyone, everywhere deserves access to affordable quality medicines.

MORE >>

OUR BUSINESSES

Focused on delivering life-changing
therapies to patients everywhere.

GENERICS

BIOSIMILARS

RESEARCH SERVICES

NOVEL BIOLOGICS

GLOBAL PRESENCE

0

+

Countries

0

+

Employees

0

+

Patents Granted

0

+

Registered Trademarks

NEWS

Biocon Biologics: Enabling Equitable Access to Affordable Healthcare

Biocon’s Q3 FY26 Earnings Call was be held on 13th Feb, 2026 at 9 AM (IST)

MORE >>

Biocon_Integrated_Annual_Report_2025-hp-thumb-v1

INTEGRATED ANNUAL REPORT 2025

Accelerating Reach.

Expanding Access. Propelling Growth.

VIEW >>

Biocon_BRSR_GRI_ESG_Databook_2025-hp-thumb-v1

BRSR & ESG DATA BOOK - 2025

Accelerating Reach.

Expanding Access. Propelling Growth.

View >>

Governance

GOVERNANCE

Behind consistent growth is good governance.

MORE >>

RESPONSIBILITY

Transforming
tomorrow.

Biocon is committed to address the world’s developmental challenges

More >>